Brokerages expect Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to post earnings per share of ($0.15) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Adamis Pharmaceuticals’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.15). The company is expected to announce its next earnings results on Thursday, March 29th.
According to Zacks, analysts expect that Adamis Pharmaceuticals will report full-year earnings of ($0.79) per share for the current fiscal year, with EPS estimates ranging from ($0.79) to ($0.78). For the next year, analysts anticipate that the firm will post earnings of ($0.64) per share, with EPS estimates ranging from ($0.67) to ($0.60). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Adamis Pharmaceuticals.
A number of equities research analysts have weighed in on ADMP shares. Maxim Group set a $14.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 5th. B. Riley set a $10.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 30th. Zacks Investment Research upgraded shares of Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, ValuEngine cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $10.33.
Adamis Pharmaceuticals (NASDAQ ADMP) opened at $3.60 on Wednesday. The company has a quick ratio of 3.79, a current ratio of 3.93 and a debt-to-equity ratio of 0.06. Adamis Pharmaceuticals has a 52 week low of $3.20 and a 52 week high of $6.45.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.